Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2015, Vol. 42 Issue (4): 427-428    DOI: 10.12891/ceog1962.2015
Original Research Previous articles | Next articles
Mid-luteal phase injection of subcutaneous leuprolide acetate improves live delivered pregnancy and implantation rates in younger women undergoing in vitro fertilization-embryo transfer (IVF-ET)
J.H. Check1, 2, *(), C. Wilson2, R. Cohen2, 3, J.K. Choe1, 2, D. Corley1, 2
1Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ
2Cooper Institute for Reproductive Hormonal Disorders, P.C. Marlton, NJ
3Philadelphia College of Osteopathic Medicine, Department of Obstetrics and Gynecology, Philadelphia, PA (USA)
Download:  PDF(75KB)  ( 14 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: To see if the single injection of one mg of the gonadotropin releasing hormone agonist (GnRHa) leuprolide acetate given in the mid-luteal phase can increase live delivered pregnancy and implantation rates. Furthermore the purpose was to determine if improvement was found, did the mechanism involve increased secretion of human chorionic gonadotropin (hCG). Materials and Methods: A prospective study was conducted in women aged ≤ 35 who were undergoing in vitro fertilization-embryo transfer (IVF-ET). They were advised of data from Tesarik et al. and a previous pilot study conducted in the present IVF center showing improved pregnancy rates with the injection of a GnRHa three days after embryo transfer. They were offered the option of returning for a one-mg injection s.c. of leuprolide acetate or not. Clinical and live delivered pregnancy rates were compared according to those taking or not the leuprolide acetate one-mg injection. Chi-square analysis was used for statistical comparisons. Serum beta-hCG levels were compared between those conceiving with or without the extra injection of leuprolide. Results: There was a non-significant trend for higher live delivered pregnancy rates in those taking leuprolide (47.8%, 64/134) vs. those not taking it (38.6%, 76/197). For those pregnant there was no difference in hCG levels according to taking the GnRHa or not. Conclusions: The 25% increased live delivered pregnancy rate per transfer was insufficiently powered to detect a significant difference. The results do justify continuing the study. Perhaps the difference could be wider using a slightly older age group whose embryos are frequently less hearty.
Key words:  Luteal phase      Gonadotropin releasing hormone agonists      Leuprolide acetate      In vitro fertilization-embryo transfer      Implantation     
Published:  10 August 2015     
*Corresponding Author(s):  J.H. CHECK     E-mail:  laurie@ccivf.com

Cite this article: 

J.H. Check, C. Wilson, R. Cohen, J.K. Choe, D. Corley. Mid-luteal phase injection of subcutaneous leuprolide acetate improves live delivered pregnancy and implantation rates in younger women undergoing in vitro fertilization-embryo transfer (IVF-ET). Clinical and Experimental Obstetrics & Gynecology, 2015, 42(4): 427-428.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog1962.2015     OR     https://ceog.imrpress.com/EN/Y2015/V42/I4/427

[1] Suchada Mongkolchaipak, Sirivipa Piyamongkol, Chutithep Teekaput, Rungthiwa Sirapat, Wanwisa Suriya, Tawiwan Pantasri, Theera Tongsong, Wirawit Piyamongkol. Successful strategy of comprehensive pre-implantation genetic testing for Duchenne muscular dystrophy and chromosome balance using karyomapping and fluorescent PCR[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1167-1177.
[2] A. Yaylalı, M. Bakacak, Z. Bakacak, F. Tolun. An investigation of the effects on follicular-embryonal development and pregnancy outcomes of serum and follicular fluid ischemia-modified albumin in cases of unexplained infertility receiving in vitro fertilization treatment[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 835-839.
[3] M. Elmahdy, I. Elfourtia, H. Maghraby. Office hysteroscopy in cases of recurrent implantation failure; Do or not to do[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 723-728.
[4] M.S. Jo, H.J. Lee, Y.J. Lee, S.C. Kim, J.K. Joo, K.S. Lee. Which is the safer method for trophectoderm biopsy in mouse blastocyst, mechanical or laser?[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 27-30.
[5] E.G. Aydeniz, U. Sari, T.U.K. Dilek. Pregnancy success rate at recurrent implantation failure patients after hysteroscopic endometrial injury: preliminary study[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 709-712.
[6] J. He, L. Zou, L. Wang, S. Zhuang. Effects of regulatory T cells, natural killer cells, and natural killer T cells on immunosuppression therapy in patients with recurrent embryo implantation failure[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 606-610.
[7] J.H. Check, C. Dietterich, M. Lowney, V. Sapoznikov, R. Difilippo, J. Giangreco, K. Clarkson. Adjusting progesterone (P) dosage to compensate for a non-homogeneous hyperechogenic (HH) echo pattern three days after embryo transfer[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 356-358.
[8] J.H. Check, J. Liss, D. Check. The beneficial effect of luteal phase support on pregnancy rates in women with unexplained infertility[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 447-449.
[9] J.H. Check, D. Summers, D. Horwath, J.K. Choe. Preimplantation genetic diagnosis for a single gene mutation for succinate dehydrogenase subunit B (the genetic basis for malignant paraganglioma) with successful pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 473-475.
[10] J.H. Check, M.P. Dougherty. Use of sympathomimetic amines to correct premenstrual urticaria and anaphylaxis[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 309-312.
[11] Jianping Zhang, Fang Yang, Yaoqin Wang, Yonglian Wang, Hongmei Liang, Xueqing Wu. Effect of differential endometrial injury timing on frozen-thawed embryo transfer pregnancy outcomes[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 118-122.
[12] Turgut Aydin, Huseyin Aksoy, Ozge Idem Karadag, Ulku Aksoy, Elif Cinar. A comparative study on therapeutic outcomes and clinical implications of transvaginal and transabdominal guidance during embryo transfer[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 823-827.
[13] J.H. Check. The pros and cons of the requirement by the Society for Assisted Reproductive Technology (SART) for their members who perform in vitro fertilization and related procedures to report their pregnancy rates to the center for disease control[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 155-158.
[14] S.A. Hebeisha, F.S. Moiety, M. Samir, M. Hussein. Effect of endometrial injury on implantation and pregnancy rates: a randomised controlled trial[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(1): 105-108.
[15] J. Kojima, H. Ito, Y. Thapa, E. Hasegawa, N. Kuji, K. Isaka. Isoflavone increases the mRNA expression levels of IL-6 signal transducer glycoprotein 130 in human endometrial glandular cells[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(4): 572-576.
No Suggested Reading articles found!